Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EPS (Weighted Average and Diluted) (2021 - 2025)

Historic EPS (Weighted Average and Diluted) for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $0.23.

  • Kiniksa Pharmaceuticals International's EPS (Weighted Average and Diluted) rose 22777.78% to $0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.45, marking a year-over-year increase of 44615.38%. This contributed to the annual value of -$0.6 for FY2024, which is 40236.97% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported EPS (Weighted Average and Diluted) of $0.23 as of Q3 2025, which was up 22777.78% from $0.23 recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year EPS (Weighted Average and Diluted) high stood at $3.18 for Q3 2022, and its period low was -$0.72 during Q1 2021.
  • Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.18 (2023), whereas its average is $0.09.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first soared by 82272.73% in 2022, then tumbled by 13456.66% in 2024.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's EPS (Weighted Average and Diluted) stood at -$0.52 in 2021, then surged by 341.75% to $1.26 in 2022, then crashed by 71.36% to $0.36 in 2023, then tumbled by 134.57% to -$0.12 in 2024, then skyrocketed by 284.83% to $0.23 in 2025.
  • Its EPS (Weighted Average and Diluted) was $0.23 in Q3 2025, compared to $0.23 in Q2 2025 and $0.11 in Q1 2025.